{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/51340"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/51340","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"Investigating the history of cancer and its impact on multiple myeloma treatment methodologies and the emergence of monoclonal antibody maintenance therapy: daratumumab (DARA) a systematic review of the literature","abstract":"This thesis paper addresses the general history, epidemiology and pathogenesis of cancer, specifically defining a prevalent and incurable subtype of cancer, multiple myeloma (MM), and its sequelae within the human body while outlining the evolution of various categories of therapy used for the treatment of cancer and its impact on our contemporary understanding of this disease. In summary, the intent of this composition aims to feature the recent emergences in treatment methodologies, explicitly investigating the utilization of monoclonal antibodies against multiple myeloma and highlighting a promising new drug known as daratumumab (DARA) and the science behind its unique anti-cancer mechanisms, both solo and in tandem with other known cancer drug therapies, and its latest achievements in clinical trials.","abstract_html":"This thesis paper addresses the general history, epidemiology and pathogenesis of cancer, specifically defining a prevalent and incurable subtype of cancer, multiple myeloma (MM), and its sequelae within the human body while outlining the evolution of various categories of therapy used for the treatment of cancer and its impact on our contemporary understanding of this disease. In summary, the intent of this composition aims to feature the recent emergences in treatment methodologies, explicitly investigating the utilization of monoclonal antibodies against multiple myeloma and highlighting a promising new drug known as daratumumab (DARA) and the science behind its unique anti-cancer mechanisms, both solo and in tandem with other known cancer drug therapies, and its latest achievements in clinical trials.","abstract_has_math":false,"creators":["Gravenstede, Melanie Beth"],"institution":"Boston University","degree_name":"Master of Science","degree_level":"masters","degree_discipline":"Medical Sciences","degree_department":null,"school":null,"contributors":[],"advisors":["Bragdon, Beth C."],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024","date_published":"2024","updated_at":"2026-11-18T20:27:03Z","subjects":["Oncology","Biology","Health sciences","Cancer","Daratumumab","Monoclonal antibody","Multiple myeloma"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2144/51340","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/51340","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F51340","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Bragdon, Beth C."]},{"key":"dc:creator","label":"Author","values":["Gravenstede, Melanie Beth"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2025-09-26T16:03:44Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2025-09-26T16:03:44Z"]},{"key":"dc:date.issued","label":"Date","values":["2024"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2025-09-26T16:02:04Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Medical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["masters"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Oncology","Biology","Health sciences","Cancer","Daratumumab","Monoclonal antibody","Multiple myeloma"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/51340"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["2024"]},{"key":"dc:description.abstract","label":"Abstract","values":["This thesis paper addresses the general history, epidemiology and pathogenesis of cancer, specifically defining a prevalent and incurable subtype of cancer, multiple myeloma (MM), and its sequelae within the human body while outlining the evolution of various categories of therapy used for the treatment of cancer and its impact on our contemporary understanding of this disease. In summary, the intent of this composition aims to feature the recent emergences in treatment methodologies, explicitly investigating the utilization of monoclonal antibodies against multiple myeloma and highlighting a promising new drug known as daratumumab (DARA) and the science behind its unique anti-cancer mechanisms, both solo and in tandem with other known cancer drug therapies, and its latest achievements in clinical trials."]},{"key":"dc:title","label":"Title","values":["Investigating the history of cancer and its impact on multiple myeloma treatment methodologies and the emergence of monoclonal antibody maintenance therapy: daratumumab (DARA) a systematic review of the literature"]}]}],"canonical_facts":{"dc:contributor.advisor":["Bragdon, Beth C."],"dc:creator":["Gravenstede, Melanie Beth"],"dc:date.accessioned":["2025-09-26T16:03:44Z"],"dc:date.available":["2025-09-26T16:03:44Z"],"dc:date.issued":["2024"],"dc:date.updated":["2025-09-26T16:02:04Z"],"dc:description":["2024"],"dc:description.abstract":["This thesis paper addresses the general history, epidemiology and pathogenesis of cancer, specifically defining a prevalent and incurable subtype of cancer, multiple myeloma (MM), and its sequelae within the human body while outlining the evolution of various categories of therapy used for the treatment of cancer and its impact on our contemporary understanding of this disease. In summary, the intent of this composition aims to feature the recent emergences in treatment methodologies, explicitly investigating the utilization of monoclonal antibodies against multiple myeloma and highlighting a promising new drug known as daratumumab (DARA) and the science behind its unique anti-cancer mechanisms, both solo and in tandem with other known cancer drug therapies, and its latest achievements in clinical trials."],"dc:identifier.uri":["https://hdl.handle.net/2144/51340"],"dc:language.iso":["en_US"],"dc:subject":["Oncology","Biology","Health sciences","Cancer","Daratumumab","Monoclonal antibody","Multiple myeloma"],"dc:title":["Investigating the history of cancer and its impact on multiple myeloma treatment methodologies and the emergence of monoclonal antibody maintenance therapy: daratumumab (DARA) a systematic review of the literature"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Medical Sciences"],"thesis:degree_level":["masters"],"thesis:degree_name":["Master of Science"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-18T20:27:03Z"}